8-K: Adverum Biotechnologies Acquired by Eli Lilly Subsidiary

Adverum Biotechnologies, Inc. has completed its merger with Flying Tigers Acquisition Corporation, a wholly-owned subsidiary of Eli Lilly and Company, following a successful tender offer.

Summary

• Adverum Biotechnologies, Inc. completed its merger with Flying Tigers Acquisition Corporation, a direct wholly-owned subsidiary of Eli Lilly and Company, on December 9, 2025.
• The tender offer, which expired on December 8, 2025, resulted in 16,493,335 shares, or approximately 64% of outstanding shares, being validly tendered and not withdrawn.
• The Minimum Tender Condition and all other conditions to the Offer were satisfied.
• Shareholders received $3.56 per share in cash, plus one non-tradable contingent value right (CVR) representing up to an aggregate of $8.91 per CVR upon achievement of specified milestones.
• The merger was completed under Section 251(h) of the DGCL, without a stockholder meeting or vote.
• All outstanding Company Stock Options with an exercise price less than the Closing Amount, Company RSUs, and Company PSUs were cancelled and converted into the right to receive cash and CVRs.
• Out-of-the-Money Options (exercise price equal to or greater than the Closing Amount) were cancelled for no consideration if unexercised prior to the Effective Time.
• Company PSU grants covering 1,959,880 shares became effective and were treated according to the merger terms.
• The company will be delisted from Nasdaq and deregistered with the SEC, terminating its public reporting obligations.

Sentiment

Score: 7

Explanation: The successful completion of the merger provides a clear exit for shareholders at the agreed-upon price, plus potential upside from CVRs. The company transitions to a private entity under a major pharmaceutical firm.

Positives

• The successful completion of the merger provides immediate cash and potential future contingent payments to Adverum shareholders.
• The tender offer achieved the minimum tender condition with approximately 64% of shares tendered.
• Equity award holders (stock options, RSUs, PSUs) are compensated as part of the transaction.

Negatives

• Adverum Biotechnologies, Inc. ceases to be an independent publicly traded company.
• Shares will be delisted from Nasdaq and deregistered with the SEC, ending public trading and reporting.
• Out-of-the-Money Options were cancelled for no consideration if not exercised prior to the Effective Time.

Risks

• Former public shareholders will no longer have a liquid market for Adverum shares.
• The value of the Contingent Value Rights (CVRs) is dependent on the achievement of future specified milestones, which are uncertain.
• The company's strategic direction and operational focus will now be determined by Eli Lilly and Company, potentially differing from its prior independent path.

Future Outlook

Adverum Biotechnologies, Inc. will operate as a direct wholly-owned subsidiary of Eli Lilly and Company. Its shares will be delisted from Nasdaq, and its SEC reporting obligations will terminate.

Industry Context

This acquisition reflects ongoing consolidation and strategic investments within the biotechnology sector, where larger pharmaceutical companies acquire smaller biotech firms for their pipeline assets, technology, or market position.

Management Changes

Corporate Governance

Related Party Transactions

• The merger itself is a transaction between Adverum Biotechnologies, Inc. and Eli Lilly and Company (Parent) and its subsidiary, Flying Tigers Acquisition Corporation (Purchaser).
• The Cash Consideration for the acquisition was funded through Parent's cash on hand and/or borrowings under its commercial paper program.

Stakeholder Impact

• Shareholders: Received $3.56 per share in cash and one CVR for potential future payments, losing their public trading liquidity.
• Employees/Consultants: Those with Company Stock Options (in-the-money), RSUs, and PSUs received cash and CVRs in exchange for their equity awards.
• Company (Adverum): Becomes a direct wholly-owned subsidiary of Eli Lilly, losing its independent public status and having its management and governance restructured.
• Eli Lilly: Gains full control of Adverum Biotechnologies, integrating its assets and operations.

Next Steps

• Nasdaq will suspend trading and delist Adverum shares.
• The Company will file Form 25 with the SEC to delist and deregister shares under Section 12(b) of the Exchange Act.
• The Company intends to file Form 15 with the SEC to terminate registration under Section 12(g) and suspend reporting obligations under Sections 13 and 15(d) of the Exchange Act.

Key Dates

Keywords

Adverum Biotechnologies, Eli Lilly, merger, acquisition, tender offer, CVR, contingent value right, delisting, biotechnology, pharmaceutical, corporate governance, 8-K, SEC filing